Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AIMD NASDAQ:ITRM NASDAQ:LVTX NYSE:VNRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$4.01+3.6%$3.45$2.00▼$5.00$19.13M2.25830,296 shs89,210 shsITRMIterum Therapeutics$0.76+0.6%$0.71$0.61▼$3.02$36.08M3.24623,154 shs986,012 shsLVTXLAVA Therapeutics$1.58-2.5%$1.54$0.85▼$2.09$41.56M0.5223,362 shs71,013 shsVNRXVolitionRx$0.65-0.3%$0.65$0.40▼$0.94$69.72M1.27200,549 shs193,514 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos+0.26%+11.85%+10.89%+21.32%+57.93%ITRMIterum Therapeutics+8.57%+13.43%+12.06%-28.30%-23.05%LVTXLAVA Therapeutics+0.62%+3.85%+3.18%+19.12%-4.14%VNRXVolitionRx+0.81%-4.24%+7.97%-1.66%-17.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAIMDAinos$4.01+3.6%$3.45$2.00▼$5.00$19.13M2.25830,296 shs89,210 shsITRMIterum Therapeutics$0.76+0.6%$0.71$0.61▼$3.02$36.08M3.24623,154 shs986,012 shsLVTXLAVA Therapeutics$1.58-2.5%$1.54$0.85▼$2.09$41.56M0.5223,362 shs71,013 shsVNRXVolitionRx$0.65-0.3%$0.65$0.40▼$0.94$69.72M1.27200,549 shs193,514 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAIMDAinos+0.26%+11.85%+10.89%+21.32%+57.93%ITRMIterum Therapeutics+8.57%+13.43%+12.06%-28.30%-23.05%LVTXLAVA Therapeutics+0.62%+3.85%+3.18%+19.12%-4.14%VNRXVolitionRx+0.81%-4.24%+7.97%-1.66%-17.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAIMDAinos 1.00SellN/AN/AITRMIterum Therapeutics 2.00Hold$9.001,076.78% UpsideLVTXLAVA Therapeutics 1.86Reduce$2.6969.94% UpsideVNRXVolitionRx 3.00Buy$3.50440.12% UpsideCurrent Analyst Ratings BreakdownLatest AIMD, ITRM, LVTX, and VNRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025ITRMIterum TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025LVTXLAVA TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/30/2025VNRXVolitionRxHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$2.509/29/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.009/27/2025AIMDAinosWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025ITRMIterum TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025LVTXLAVA TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/10/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/15/2025VNRXVolitionRxD. Boral CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$5.008/5/2025LVTXLAVA TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$1.50 ➝ $1.248/5/2025LVTXLAVA TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$3.00 ➝ $1.50(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAIMDAinos$20K956.39N/AN/A$5.51 per share0.73ITRMIterum TherapeuticsN/AN/AN/AN/A($0.15) per shareN/ALVTXLAVA Therapeutics$4.99M8.33N/AN/A$1.06 per share1.49VNRXVolitionRx$1.32M52.85N/AN/A($0.11) per share-5.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAIMDAinos-$14.86M-$4.99N/A∞N/AN/A-108.25%-56.94%11/5/2025 (Estimated)ITRMIterum Therapeutics-$24.77M-$0.85N/A∞N/AN/AN/A-65.01%11/13/2025 (Estimated)LVTXLAVA Therapeutics-$25.11M-$1.05N/AN/AN/AN/A-106.29%-38.24%12/9/2025 (Estimated)VNRXVolitionRx-$35.32M-$0.25N/A∞N/A-2,321.14%N/A-163.39%N/ALatest AIMD, ITRM, LVTX, and VNRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025AIMDAinosN/A-$0.99N/A-$0.99N/AN/A8/13/2025Q2 2025LVTXLAVA Therapeutics-$0.28-$0.32-$0.04-$0.32N/AN/A8/5/2025Q2 2025ITRMIterum Therapeutics-$0.13-$0.16-$0.03-$0.16N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAIMDAinosN/AN/AN/AN/AN/AITRMIterum TherapeuticsN/AN/AN/AN/AN/ALVTXLAVA TherapeuticsN/AN/AN/AN/AN/AVNRXVolitionRxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAIMDAinos0.962.882.61ITRMIterum TherapeuticsN/A2.692.52LVTXLAVA TherapeuticsN/A10.7810.78VNRXVolitionRxN/A0.220.22Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAIMDAinosN/AITRMIterum Therapeutics9.21%LVTXLAVA TherapeuticsN/AVNRXVolitionRx8.09%Insider OwnershipCompanyInsider OwnershipAIMDAinos10.39%ITRMIterum Therapeutics2.40%LVTXLAVA Therapeutics9.50%VNRXVolitionRx10.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAIMDAinos404.77 million4.28 millionNot OptionableITRMIterum Therapeutics1047.17 million46.04 millionNot OptionableLVTXLAVA Therapeutics6026.31 million23.81 millionOptionableVNRXVolitionRx80107.60 million80.80 millionOptionableAIMD, ITRM, LVTX, and VNRX HeadlinesRecent News About These CompaniesVolition Sponsors Upcoming GenomeWeb WebinarOctober 2, 2025 | prnewswire.comHC Wainwright Reiterates "Buy" Rating for VolitionRx (NYSE:VNRX)October 2, 2025 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for VolitionRx (NYSE:VNRX)September 30, 2025 | marketbeat.comD. Boral Capital Maintains VolitionRx (VNRX) Buy RecommendationSeptember 30, 2025 | msn.comVolitionRx (NYSE:VNRX) Earns Buy Rating from D. Boral CapitalSeptember 29, 2025 | marketbeat.comVolition Signs Co-Marketing and Services Agreement with HologicSeptember 29, 2025 | prnewswire.comD. Boral Capital Reiterates "Buy" Rating for VolitionRx (NYSE:VNRX)September 12, 2025 | marketbeat.comVolitionRx signs first human out licensing deal for APSSeptember 9, 2025 | msn.comVolition Signs First Human Out Licensing DealSeptember 9, 2025 | prnewswire.comVolitionRx Limited (AMEX:VNRX) Q2 2025 Earnings Call TranscriptAugust 16, 2025 | msn.comVolitionRx Limited (VNRX) Q2 2025 Earnings Call TranscriptAugust 15, 2025 | seekingalpha.comVolitionRx reports Q2 revenue $400K, consensus $375.72KAugust 14, 2025 | msn.comVolitionRx Limited Announces Second Quarter 2025 Financial Results and Business UpdateAugust 14, 2025 | prnewswire.comInsights into VolitionRX's Upcoming EarningsAugust 14, 2025 | benzinga.comVolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update | ...August 8, 2025 | gurufocus.comVolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business UpdateAugust 8, 2025 | prnewswire.comVolitionRx Limited (NYSE:VNRX) Director Acquires $50,000.00 in StockAugust 7, 2025 | insidertrades.comVolitionRx Announces Pricing of $1.2 Million Registered Direct OfferingAugust 4, 2025 | prnewswire.comNu.Q® Discover Expands Global Adoption and Epigenetic InnovationJuly 16, 2025 | prnewswire.comVolitionRx Limited (VNRX) - Yahoo FinanceJuly 11, 2025 | nz.finance.yahoo.comVolition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of NucleosomesJuly 8, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAIMD, ITRM, LVTX, and VNRX Company DescriptionsAinos NASDAQ:AIMD$4.01 +0.14 (+3.62%) As of 04:00 PM EasternAinos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women's health, pneumonia, Ainos Pen, AI Nose, and other products. Ainos, Inc. was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. The company was incorporated in 1984 and is based in San Diego, California.Iterum Therapeutics NASDAQ:ITRM$0.76 +0.00 (+0.63%) Closing price 04:00 PM EasternExtended Trading$0.75 -0.01 (-1.80%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.LAVA Therapeutics NASDAQ:LVTX$1.58 -0.04 (-2.47%) Closing price 04:00 PM EasternExtended Trading$1.59 +0.01 (+0.63%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.VolitionRx NYSE:VNRX$0.65 0.00 (-0.31%) Closing price 04:00 PM EasternExtended Trading$0.66 +0.01 (+1.54%) As of 05:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End Will Firefly’s $855M SciTec Acquisition Ignite a Stock Re-Rating? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.